相关实验视频
Updated: May 13, 2026

07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
通过针对缺氧诱导的转录因子复合体设计的二次性脊髓基基基托皮佩拉来抑制瘤生长
Ramin Dubey1, Michael D Levin, Lajos Z Szabo
1Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, 1985 Zonal Ave., PSC B15C, HSC 9121, Los Angeles, California 90089, USA.
Journal of the American Chemical Society
|March 2, 2013
概括
一种新型化合物,二度性皮二二二 (ETP 2),有效抑制缺氧诱导因子1 (HIF1) 的活性. 这种有针对性的方法在减少瘤生长和克服癌症治疗中的抗治疗性方面显著有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 低氧是一种低氧状态,在固体瘤中普遍存在,并与癌症进展,转移和治疗耐药性有关.
- 缺氧诱导因子1 (HIF1) 是一个关键的转录因子,调解细胞对缺氧的反应,通过各种机制促进瘤生长.
- 准HIF1转录活性是针对攻击性癌症的潜在治疗策略.
研究的目的:
- 为了研究一种设计的转录抗剂,二度性白二二二二二 (ETP 2) 在抑制HIF1活性方面的有效性.
- 在临床前癌症模型中评估ETP 2的抗瘤作用.
主要方法:
- 使用一种新的同位氧化合方法合成ETP2.
- 该研究评估了ETP 2在乳腺癌和肺癌细胞系中抑制HIF1诱导的基因表达 (VEGFA,LOX,Glut1,c-Met) 的能力.
- 在乳腺癌模型中使用静脉内显微镜评估了抗瘤疗效.
主要成果:
- ETP 2选择性地破坏了HIF1α与p300/CBP联合激活剂的相互作用,降低了低氧诱导基因的调节.
- 在乳腺癌模型中, (±) -ETP 2 和 meso-ETP 2 均表现出显著的抗瘤功效.
- 用ETP 2 (1 mg/kg) 治疗导致瘤生长迅速回落,持续长达14天.
结论:
- 设计的二维ETP,如ETP2,通过抑制HIF1转录活性,代表了一种新的治疗方法.
- 这一策略有可能克服缺氧驱动的瘤生长和癌症治疗阻力.
相关概念视频
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
